# 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results

> **NCT02355574** · — · TERMINATED · sponsor: **Castle Biosciences Incorporated** · enrollment: 301 (actual)

## Conditions studied

- Cutaneous Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02355574
- **Lead sponsor:** Castle Biosciences Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2021-02
- **Final completion:** 2021-07
- **Target enrollment:** 301 (ACTUAL)
- **Why stopped:** Study endpoints completed with lower than anticipated enrollment. Last patient enrolled completed final visit February 2021.
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02355574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02355574, "5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02355574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*